← Back to Home

A New Option for Relapse During Steroid Tapering: Cosentyx Receives EU Approval for Polymyalgia Rheumatica

The new indication covers adults with an inadequate response to steroids or relapse during tapering. A Phase III trial showed an increased likelihood of sustained remission at one year, but the current announcement does not provide enough information to fully assess the magnitude of benefit or long-term risks.

By SURL BioNews

For patients with polymyalgia rheumatica, the challenge of treatment often extends beyond relieving pain to maintaining disease stability as steroids are reduced. Novartis announced on October 21 that the European Commission had approved Cosentyx (secukinumab) to treat adults with an inadequate response to glucocorticoids or relapse during tapering, adding an option for patients whose disease is difficult to keep under stable control.

The decision follows an earlier regulatory review. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on September 17, recommending the addition of a polymyalgia rheumatica indication. The patient population it recommended matches the approval announced by Novartis. The committee’s scientific recommendation and the Commission’s formal approval are distinct steps in this process.

Polymyalgia rheumatica primarily affects adults over 50, commonly causing pain and stiffness in the shoulders, neck and hips that may interfere with daily activities. Steroids are a mainstay of treatment, but relapse may occur during tapering, and long-term use carries risks including osteoporosis and diabetes. Treatment therefore aims both to relieve symptoms and to reduce the burden of ongoing medication.

Secukinumab is a monoclonal antibody that directly inhibits interleukin-17A (IL-17A), working by blocking signals involved in inflammation. It was already used for psoriasis and certain inflammatory joint diseases. This approval extends its use to specific patients with polymyalgia rheumatica; it does not mean that the same treatment strategy is appropriate for all newly diagnosed patients.

The Phase III REPLENISH trial supporting the approval used a randomized, double-blind, placebo-controlled design, comparing two doses of secukinumab with placebo, with all groups following a 24-week steroid tapering regimen. Novartis said the sustained remission rate at week 52 was twice that of placebo. However, the press release did not provide absolute remission rates for each group, confidence intervals or complete adverse event data. The description of “twice” alone makes it difficult to determine how many additional patients out of every 100 would actually benefit.

Novartis said the trial’s safety results were consistent with the existing safety data for the drug. However, this general statement cannot replace complete data, nor does it directly establish that long-term steroid complications have consequently been reduced. The significance of this approval is that eligible patients now have another route to maintaining disease control. Further data are still needed to clarify its relative benefits compared with other treatments and the outcomes of longer-term use.

References

  1. Novartis
  2. European Medicines Agency